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Abstract
 
Limited oxygen delivery to tissues (hypoxia) is common in a variety of disease states. A number
of parallels exist between hypoxia and acute inflammation, including the observation that both
influence vascular permeability. As such, we compared the functional influence of activated
polymorphonuclear leukocytes (PMN) on normoxic and posthypoxic endothelial cells. Initial
studies indicated that activated PMN preferentially promote endothelial barrier function in
posthypoxic endothelial cells (
 
 
 
60% increase over normoxia). Extension of these findings
identified at least one soluble mediator as extracellular adenosine triphosphate (ATP). Subse-
quent studies revealed that ATP is coordinately hydrolyzed to adenosine at the endothelial cell
surface by hypoxia-induced CD39 and CD73 (
 
 
 
20-and 
 
 
 
12-fold increase in mRNA, respec-
tively). Studies in vitro and in 
 
cd39
 
-null mice identified these surface ecto-enzymes as critical
control points for posthypoxia-associated protection of vascular permeability. Furthermore, insight
gained through microarray analysis revealed that the adenosine A
 
2B
 
 receptor (AdoRA
 
2B
 
) is
selectively up-regulated by hypoxia (
 
 
 
5-fold increase in mRNA), and that AdoRA
 
2B
 
 antagonists
effectively neutralize ATP-mediated changes in posthypoxic endothelial permeability. Taken
together, these results demonstrate transcription coordination of adenine nucleotide and nucleo-
side signaling at the vascular interface during hypoxia.
Key words: adenosine • ectonucleotidase • endothelium • neutrophil • inﬂammation
 
Introduction
 
The study of physiologic adaptation and pathophysiologic
response to hypoxia is presently an area of intense investi-
gation. Recent reports suggest that both transcriptional and
nontranscriptional hypoxia pathways may contribute to a
broad range of diseases, and that a number of parallels exist
between tissue responses to hypoxia and to acute inflamma-
tion (1). For example, during episodes of hypoxia, PMN
are mobilized from the intravascular space to the intersti-
tium, and such responses may contribute significantly to
tissue damage during consequent reperfusion injury (2–4).
Moreover, myeloid cell migration to sites of inflammation
are highly dependent on hypoxia-adaptive pathways (5). As
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such, emigration of PMN through the endo- and epithelial
barrier may lead to a disruption of such tissue barriers (6–8)
and such a setting creates the potential for extravascular
fluid leakage and subsequent edema formation (9, 10).
However, with some exceptions, most episodes of hypoxia
and/or ischemia-reperfusion are self-limiting, suggesting
that endogenous protective mechanisms may exist to fortify
the vascular barrier during such insults.
Previous studies have indicated that activated PMN re-
lease a number of soluble mediators, which regulate vascu-
lar permeability during transmigration. For example, PMN
have been demonstrated to actively release both glutamate
(3) and adenine nucleotides (in the form of AMP, which
through a one step metabolic conversion liberates adeno-
sine at the vascular surface; reference 11). Glutamate and
adenosine liberated by this process have been shown to
promote microvascular endothelial barrier, and as such,
may provide innate pathways to reestablish endothelial cell-
cell contact following PMN transmigration (11–13).
In the present studies, we sought to determine whether
hypoxia might differentially influence vascular permeability
in response to activated PMN. Somewhat surprisingly, ini-
tial results revealed that posthypoxic endothelia demon-
strated increased protective responses to activated PMN.
Studies aimed at isolating potentially novel factors in this
pathway revealed that PMN-derived ATP was, at least in
part, responsible for the increase observed in the posthy-
poxic endothelium. Indeed, enhanced extracellular metab-
olism and signaling after hypoxia were explained by
transcriptional increases in functional surface apyrase
(CD39), nucleotidase (CD73), and adenosine A
 
2B
 
-receptor
(AdoRA
 
2B
 
), respectively. Such studies identify a coordi-
nated, barrier-protective response initiated by endothelial
preexposure to hypoxia.
 
Materials and Methods
 
Endothelial Cell Isolation and Culture.
 
Human microvascular
endothelial cells (HMEC-1) were a gift of Francisco Candal, Cen-
ters for Disease Control, Atlanta, GA (14) and were harvested and
cultured by a modification of methods described previously (3,
11). In brief, HMEC-1 were harvested with 0.1% trypsin and in-
cubated at 37
 
 
 
C in 95% air/5% CO
 
2
 
. Culture medium was sup-
plemented with heat-inactivated fetal bovine serum, penicillin,
streptomycin, 
 
l
 
-glutamine, epidermal growth factor, and hydro-
cortisone. Where indicated, primary human microvascular endo-
thelial cells (HMVEC; Cascade Biologics) or bovine aortic endo-
thelial cells (BAE; American Type Culture Collection) were
cultured as described previously (11, 12). For preparation of ex-
perimental monolayers, confluent endothelial cells were seeded at
 
 
 
10
 
5
 
 cells/ cm
 
2
 
 onto either permeable polycarbonate inserts or
100-mm Petri dishes. Endothelial cell purity was assessed by phase
microscopic “cobblestone” appearance and uptake of fluorescent
acetylated low-density lipoprotein. For hypoxic exposure, conflu-
ent endothelial monolayers were subjected to indicated periods of
hypoxia (pO
 
2
 
 20 torr) as described previously (3).
 
Isolation of Human Neutrophils.
 
PMN were freshly isolated
from whole blood obtained by venipuncture from human volun-
teers and anticoagulated with acid citrate/dextrose (2). Platelets,
 
plasma, and mononuclear cells were removed by aspiration from
the buffy coat following centrifugation through Histopaque
 
®
 
-
1077 at 400 
 
g
 
 for 30 min at 25
 
 
 
C. Erythrocytes were removed us-
ing a 2% gelatin sedimentation technique. Residual erythrocytes
were removed by lysis in cold NH
 
4
 
Cl buffer. Remaining cells were
 
 
 
97% PMN as assessed by microscopic evaluation. PMN were
studied within 2 h of their isolation.
 
Preparation of Activated PMN Supernatants.
 
Freshly isolated
PMN (10
 
8
 
 cells/ml in HBSS with 10
 
 
 
6
 
 M FMLP) were incu-
bated end-over-end for 1 min at 37
 
 
 
C (based on pilot experi-
ments; unpublished data). PMN were then immediately pelleted
(1,000 
 
g
 
 for 20 s, 4
 
 
 
C) and supernatants filtered (0.45 
 
 
 
m; Phe-
nomenex). For initial experiments isolating active PMN fractions,
10
 
8
 
 PMN/ml were activated, cells were removed by pelleting and
supernatants were filtered (0.2 
 
 
 
m). Resultant cell-free superna-
tants were resolved by high-performance liquid chromatography
(model 1050; Hewlett-Packard) with an HP 1100 diode array de-
tector by reverse-phase on an HPLC column (Luna 5-
 
 
 
m C18,
150 
 
 
 
 4.60 mm; Phenomenex) with 100% H
 
2
 
0 mobile phase.
Ultraviolet absorption spectra were obtained throughout. 1 ml
fractions were collected, evaporated to dryness by speed-vac, re-
constituted in HBSS (20-fold concentrated) and bioactivity was
determined by permeability assay.
In experiments measuring supernatant concentrations of ATP,
100-
 
 
 
l samples were taken from PMN suspensions, immediately
spun (1,000 
 
g
 
 for 20 s, 4
 
 
 
C), filtered (0.45 
 
 
 
m), and analyzed via
HPLC. ATP was measured with a H
 
2
 
O:CH
 
3
 
CN 96:4 mobile
phase (1 ml/min). E-ATP and E-AMP were measured with a 0–50%
methanol/H
 
2
 
O gradient (10 min) mobile phase (2 ml/min). Ab-
sorbance was measured at 260 nm. UV absorption spectra were
obtained at chromatographic peaks. ATP and adenine nucleotides
were identified by their chromatographic behavior (retention
time, UV absorption spectra, and coelution with standards).
To measure the time course of ATP release from PMN, 10
 
7
 
PMN/ml were activated for indicated periods of time, superna-
tants were collected, and ATP content was quantified using
CHRONO-LUME reagent (Crono-log Corp.). Luciferase activ-
ity was assessed on a luminometer (Turner Designs Inc.) and
compared with internal ATP standards.
 
Endothelial Macromolecule Paracellular Permeability Assay.
 
Us-
ing a modification of methods previously described (11), HMEC-1
on polycarbonate permeable inserts (0.4-
 
 
 
m pore, 6.5-mm
diam; Costar Corp.) were studied 7–10 d after seeding (2–5 d after
confluency). Inserts were placed in HBSS-containing wells (0.9
ml), and HBSS (alone or with PMN, PMN supernatant, or ATP)
was added to inserts (100 
 
 
 
l). At the start of the assay (t 
 
 
 
 0),
FITC-labeled dextran 70 kD (concentration 3.5 
 
 
 
M) was added
to fluid within the insert. The size of FITC-dextran, 70 kD, ap-
proximates that of human albumin, both of which have been used
in similar endothelial paracellular permeability models (15, 16).
Fluid from opposing well (reservoir) was sampled (50 
 
 
 
l) over 60
min (t 
 
 
 
 20, 40, and 60 min). Fluorescence intensity of each sam-
ple was measured (excitation, 485 nm; emission, 530 nm; Cyto-
fluor 2300; Millipore Corp., Waters Chromatography) and FITC-
dextran concentrations were determined from standard curves
generated by serial dilution of FITC-dextran. Paracellular flux was
calculated by linear regression of sample fluorescence (11).
 
Immunoprecipitation.
 
Confluent cells were labeled with biotin,
lysed, and cell debris removed by centrifugation. Lysates were
precleared with 50 
 
 
 
l preequilibrated protein G-Sepharose (Am-
ersham Biosciences). Immunoprecipitation was performed with
mouse mAb to human CD39 (Research Diagnostics, Inc.; 5 
 
 
 
g/
ml), CD73 with mAb 1E9 (5 
 
 
 
g/ml, a gift from Dr. LindaT
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Thompson, Oklahoma Medical Research Foundation, Oklahoma
City, OK) or AdoRA
 
2B
 
 with goat polyclonal (Santa Cruz Bio-
technology, Inc.) followed by addition of 50 
 
 
 
l preequilibrated
protein G-Sepharose and overnight incubation. Washed immu-
noprecipitates were boiled in reducing sample buffer (2.5% SDS,
0.38 M Tris, pH 6.8, 20% glycerol, and 0.1% bromophenol blue),
separated by SDS-PAGE, transferred to nitrocellulose, and
blocked overnight in blocking buffer. Biotinylated proteins were
labeled with streptavidin-peroxidase and visualized by enhanced
chemiluminescence (ECL; Amersham Biosciences).
 
Transcriptional Analysis.
 
Semiquantitative RT-PCR was used
to verify endothelial CD39 mRNA regulation, as described previ-
ously (17). The PCR reaction contained 1 
 
 
 
M each of the sense
primer 5
 
 
 
-AGC AGC TGA AAT ATG CTG GC-3
 
 
 
 and the an-
tisense primer 5
 
 
 
-GAG ACA GTA TCT GCC GAA GTC C-3
 
 
 
.
The primer set was amplified using increasing numbers of cycles
of 94
 
 
 
C for 1 min, 60
 
 
 
C for 2 min, 72
 
 
 
C for 4 min, and a final ex-
tension of 72
 
 
 
C for 7 min. The PCR transcripts were visualized
on a 1.5% agarose gel containing 5 
 
 
 
g/ml of ethidium bromide.
Human 
 
 
 
-actin (sense primer, 5
 
 
 
-TGA CGG GGT CAC CCA
CAC TGT GCC CAT CTA-3
 
 
 
; and antisense primer, 5
 
 
 
-CTA
GAA GCA TTT GCG GTG GAC GAT GGA GGG-3
 
 
 
) in
identical reactions was used to control for the starting template.
In subsets of experiments, the transcriptional profile of endothe-
lial cells subjected to normobaric hypoxia (12 h) was compared in
RNA derived from control or hypoxic endothelium using quanti-
tative genechip expression arrays (Affymetrix, Inc.) as described
before (18). Where indicated, mRNA was also quantified by real-
time PCR (iCycler; Bio-Rad Laboratories Inc.), as described pre-
viously (19). The primer sets contained 1 
 
 
 
M sense and 1 
 
 
 
M an-
tisense containing SYBR Green I (Molecular Probes Inc.) in the
reaction mixture. Primer sets (sense sequence, antisense sequence,
and transcript size, respectively) for the following genes were used:
CD39 (5
 
 
 
-AGC AGC TGA AAT ATG CTG GC-3
 
 
 
, 5
 
 
 
-GAG
ACA GTA TCT GCC GAA GTC C-3
 
 
 
, 199 bp); CD73 (5
 
 
 
-
ATT GCA AAG TGG TTC AAA GTC A-3
 
 
 
, 5
 
 
 
-ACA CTT
GGC CAG TAA AAT AGG G-3
 
 
 
, 123 bp); adenosine A
 
1
 
-recep-
tor (AdoRA
 
1
 
) (5
 
 
 
-GTT CAC AGT TTT TTA TTA GTC AC-
3
 
 
 
,5
 
 
 
-AAC ATG AGT GTC AAC TCC-3
 
 
 
, 109 bp); adenosine
A
 
2A
 
-receptor (AdoRA
 
2A
 
) (5
 
 
 
-CTT GGG TTC TGA GGA AGC
AG-3
 
 
 
, 5
 
 
 
-CAG CAG CTC CTG AAC CCT AG-3
 
 
 
, 253 bp);
AdoRA
 
2B
 
 (5
 
 
 
-ATC TCC AGG TAT CTT CTC-3
 
 
 
, 5
 
 
 
-GTT
GGC ATA ATC CAC ACA G-3
 
 , 322 bp); adenosine A3-recep-
tor (AdoRA3) (5 -CTT GAT TAC TTC CAC TGA GGT GG-
3 , 5 -CAA CAT CTT CTA GGC ATC CTC C-3 , 334 bp);
and  -actin (5 -GGT GGC TTT TAG GAT GGC AAG-3 , 5 -
ACT GGA ACG GTG AAG GTG ACA G-3 , 162 bp) in identi-
cal reactions was used to control for starting template. Transcript
levels and fold change in mRNA were determined as described
previously (20). In addition, real-time PCR was performed from
RNA isolations of human saphenous vein after ex vivo exposure
to hypoxia. After approval by the institutional review board,
saphenous vein material was obtained from patients undergoing
aorta-coronary bypass surgery. Equal portions of dissected vein tis-
sue were subjected to hypoxia (pO2 20 torr) immediately after the
operation for different time points (0, 2, 8, and 24 h). After hy-
poxic exposure, total RNA was isolated from the tissues and real-
time PCR was performed as described above.
Measurement of Surface Enzyme Activity of CD39. We assessed
CD39 surface enzyme activity as described previously (18) by
quantifying the conversion of etheno-ATP (E-ATP) to etheno-
AMP (E-AMP). Briefly, HBSS (with addition of the CD73 inhib-
itor   -methylene-ADP [10  M] to prevent further metabolism
of E-AMP to E-adenosine) was added to endothelial monolayers
on a 60 mm Petri dish. After 10 min, E-ATP (final concentration
100  M) was added. Samples were taken at indicated time-points,
removed, acidified to pH 3.5 with HCl, spun (10,000 g for 20 s,
4 C), filtered (0.45  m), and frozen (–80 C) until analysis via re-
verse phase HPLC. Ratio of E-ATP (Molecular Probes Inc.) and
E-AMP (Sigma-Aldrich) was measured with a 0–50% methanol/
H2O gradient mobile phase (2 ml/min over 10 min). Absorbance
was measured at 260 nm, and ultraviolet absorption spectra were
obtained at chromatographic peaks. CD39 activity was expressed
as percent E-ATP conversion in this time frame.
CD39 Suppression with RNA Interference. HMEC-1 were ei-
ther grown on inserts or in 100 mm Petri dishes. SiRNA directed
against human CD39 (sense strand 5 -GAA UAU CCU AGC
CAU CCU UdTdT-3  and antisense strand 5 -dTdT CUU
AUA GGA UCG GUA GGA A-3 ) were designed using stan-
dard molecular tools and synthesized by Dharmacon®. A nonspe-
cific control ribonucleotide (sense strand 5 -ACU CUA UCU
GCA CGC UGA CdTdT-3  and antisense strand 5 -dTdT UGA
GAU AGA CGU GCG ACU G-3 , Dharmacon®) was used un-
der identical conditions. HMEC-1 loading was accomplished us-
ing standard conditions of Polyfect (QIAGEN) transfection (450
ng/monolayer cm2) when cells had reached 40–60% confluence.
After 12 h loading, cells were incubated in either normoxia or
hypoxia, as indicated.
In Vivo Hypoxia Model. Mice deficient in cd39 on the
C57BL/6/129 svj strain were generated, validated, and character-
ized as described previously (21). Control mice were matched ac-
cording to sex, age, and weight. Total organ vascular permeability
was quantified by intravascular administration of Evans blue as
described previously (22). For the purpose of quantifying vascular
permeability, 0.2 c.c. of Evans blue (0.5% in PBS) were injected
intravenously. Animals were then exposed to normobaric hy-
poxia (8% O2, 92% N2) or room air for 4 h (n   4 animals per
condition). After hypoxia/normoxia exposure the animals were
killed and the colon, muscle, kidney, brain, liver, and lungs were
harvested. Organ Evans blue concentrations were quantified after
formamide extraction (55 C for 2 h) by measuring absorbances at
610 nm with subtraction of reference absorbance at 450 nm. This
protocol was in accordance with NIH guidelines for use of live
animals and was approved by the Institutional Animal Care and
Use Committee at Brigham and Women’s Hospital.
Data Analysis. CD39 and CD73 bioactivity and paracellular
permeability data were compared by two-factor ANOVA, or by
Student’s t test where appropriate. Values are expressed as the
mean   SD from at least three separate experiments.
Results
Enhanced Barrier Protection to Activated PMN in Posthypoxic
Endothelial Cells. We have previously demonstrated that
during the process of transmigration, activated PMNs re-
lease soluble mediators which “reseal” endothelial mono-
layers after transit (11, 12, 23). It was further shown that
leukocyte derived AMP is at least one leukocyte-derived
factor responsible for this increase in barrier function
(measured as a decrease in paracellular permeability; refer-
ence 11). Given the association of hypoxia and acute in-
flammation (1, 24) we questioned whether posthypoxic
endothelia might differentially respond to activated PMN.
As such, we compared the influence of activated PMN onT
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786 Coordinated Nucleotide Phosphohydrolysis during Hypoxia
permeability of normoxic and posthypoxic (pO2 20 torr
for 48 h) HMEC-1. Consistent with previous work (11),
increasing numbers of activated PMN elicited a concentra-
tion-dependent increase in endothelial barrier (measured
as a decrease in paracellular flux rate of 70 kD FITC-
labeled dextran; Fig. 1 A, P   0.025 compared with no
Figure 1. Influence of PMN on perme-
ability of normoxic and posthypoxic endo-
thelia. (A) Activated PMN (10 6 M FMLP)
at indicated concentrations were added to
the apical surface of confluent normoxic
(48 h exposure to pO2 147) or posthypoxic
(48 h exposure to pO2 20 torr) HMEC-1
and permeability to FITC-dextran (70 kD)
was quantified. Transendothelial flux was cal-
culated by linear regression (4 samples over
60 min) and normalized as percent of con-
trol (HBSS). Data are derived from six mono-
layers in each condition. Data are expressed
as mean   SD of percent control flux with
HBSS only. Asterisk (*) indicates significant
differences from baseline (P   0.05) and a
cross (#) indicates differences from baseline
and from normoxia (P   0.05). (B) Super-
natants derived from activated PMN (10 6 M
FMLP for 10 min) were fractionated by
HPLC (H20 mobile phase at 1 ml/min, 1 ml
samples; inset indicates representative UV
spectra at 260 nm and indicated samples
collected at individual arrows). Samples
were concentrated 20-fold and tested for
bioactivity on normoxic or posthypoxic
HMEC-1 in a model of paracellular perme-
ability. Fraction #6 promotes barrier func-
tion in normoxic and posthypoxic endothelial
cells, whereas fraction #2 is relatively selec-
tive for posthypoxic endothelia (*, P   0.01
compared with HBSS).T
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PMN). As shown in Fig. 1 A, parallel analysis of posthy-
poxic HMEC-1 revealed a significant increase in endothe-
lial barrier protection to activated PMN, relative to nor-
moxia (P   0.01 by ANOVA). Indeed, fewer PMN were
required to elicit an equivalent increase in posthypoxic en-
dothelial barrier, with an approximate 10-fold increase in
endothelial sensitivity to PMN after hypoxia. Similar re-
sults were obtained using nonimmortalized BAE as an en-
dothelial source (unpublished data). Such results suggest
that the posthypoxic endothelium is functionally distinct
in this regard and that barrier protective pathways are en-
hanced after exposure to hypoxia.
Identification of PMN-derived ATP as a Mediator of Perme-
ability Changes in Posthypoxic Endothelial Cells. We next
sought to determine the existence of soluble mediators from
activated PMN that might contribute to enhanced barrier
protection after hypoxia. To do this, we used HPLC to
fractionate supernatants derived from activated PMN
(10 6 M for 1 min, based on pilot experiments), and tested
bioactivity of individual fractions on normoxic and posthy-
poxic endothelium. As shown in Fig. 1 B, of 10 fractions that
were isolated, fraction 6 increased endothelial barrier func-
tion in both posthypoxic and normoxic endothelial cells. In
contrast, fraction 2 was associated with an increase in barrier
Figure 2. Activated PMN rapidly release ATP. (A) Chromatographic identification of ATP in supernatants derived from activated PMN. Shown here
is a representative overlay chromatogram of activated PMN supernatant (bold line) and authentic ATP (narrow line). Inset represents an overlay UV spec-
tra derived from fraction #2 (see Fig. 1) and of authentic ATP with one dominant peak at 260 nm. (B) Time course of ATP release from activated PMN
(107 PMN/ml activated with 10 6 M FMLP). PMN were activated for indicated periods of time and supernatant ATP was quantified by luciferase assay.
Data represent mean   SD ATP/107 PMN for three separate experiments. (C) Authentic ATP selectively promotes endothelial barrier function in post-
hypoxic endothelia. Indicated concentrations of ATP were added to HMEC-1 preexposed to normoxia or hypoxia. As indicated, ATP influenced endo-
thelial permeability only in posthypoxic endothelial cells (*, P   0.025 compared with no ATP). In contrast, the addition of adenosine (Ado, 100  M)
was associated with an increase in barrier function in both normoxic and posthypoxic endothelial cells (#, P   0.01 compared with buffer alone). The ad-
dition of 8-phenyl-theophylline (8-PT at 10  M, a nonselective adenosine receptor antagonist) obviated the barrier effect of 100  M ATP in posthypoxic
endothelial cells. Data are derived from six monolayers in each condition. Data are expressed as mean   SD of percent control flux with HBSS only.T
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function only in posthypoxic endothelial cells. Parallel spec-
tral scans from eluted samples revealed dominant, single UV
peaks at 260 nm for fractions 2 and 6 (see inset Fig. 2 A), a
spectral profile consistent with nucleotides (25).
We had previously shown that PMN-derived 5 -adeno-
sinemonophosphate (AMP) promotes barrier function in
endothelial permeability assays (11). We therefore com-
pared retention times of authentic 5-AMP with the reten-
tion times of the HPLC fractions that were tested in this
experiment. The retention time of AMP was identical to
that of fraction 6 and coinjection with authentic AMP re-
vealed a single peak (unpublished data), thus identifying
fraction 6 as AMP. Further analysis of comparative nucle-
otides identified fraction 2 as ATP (based on retention
time, UV absorption spectra, and coelution with internal
ATP standards). Indeed, UV spectra analysis demonstrated
similar absorption characteristics of fraction 2 and authentic
ATP (Fig. 2 A). To verify ATP release from activated
PMN, we used standard luminometric ATP detection as-
says. As shown in Fig. 2 B, ATP rapidly accumulated in su-
pernatants derived from fMLP-activated PMN (maximal
levels 215   16 nmoles/107 PMN). Measurable levels of
ATP rapidly dissipated and approached basal levels within 5
min. These results indicate that activated PMN rapidly re-
lease ATP, and that such extracellular ATP preferentially
promotes barrier function in posthypoxic endothelial cells.
ATP Promotes Barrier Function Selectively in Posthypoxic En-
dothelial Cells. Having demonstrated that activated PMN
release ATP, we next examined the influence of ATP on
normoxic and posthypoxic endothelial paracellular perme-
ability. As shown in Fig. 2 C, the addition of ATP (range
1–100  M) did not influence normoxic endothelial per-
meability. In striking contrast, following a 48 h exposure to
hypoxia, endothelial flux rates were significantly decreased
in an ATP concentration-dependent fashion (P   0.01 by
ANOVA), and were similar to responses observed with 100
 M adenosine (Fig. 2 C). Similar results were obtained us-
ing posthypoxic, nonimmortalized BAE as an endothelial
source (60   8% decrease in permeability with 100  M
ATP, P   0.01, n   3). Such findings suggest that ATP se-
lectively promotes endothelial barrier of the posthypoxic
endothelium.
To gain insight into potential mechanisms of ATP regu-
lation of posthypoxic endothelial permeability, we rea-
soned that ATP may directly activate surface ATP recep-
tors, or alternatively, may be metabolized to adenosine at
the endothelial surface. Thus, we determined the relative
influence of adenosine in this response by using the non-
specific adenosine receptor antagonist 8-phenyltheophyl-
line (8-PT). As shown in Fig. 2 C, the permeability
changes associated with the addition of authentic ATP (100
 M) on posthypoxic endothelial cells was neutralized by
8PT (10  M, P   not significant compared with buffer
alone), indicating that the barrier protective influence ob-
served with ATP reflects adenosine receptor activation.
Prominent Role for CD39 in ATP-modulated Permeability of
Posthypoxic Endothelial Cells. Metabolism of extracellular
ATP is predominantly determined by CD39, an ecto-apy-
Figure 3. Induction of functional CD39 is by hypoxia. (A) Confluent
HMEC-1 monolayers were exposed to normoxia (pO2 147 torr, 18 h) or
hypoxia (pO2 20 torr, 18 h). Total RNA was isolated, and CD39
mRNA levels were determined by RT-PCR using semiquantitative
analysis (increasing cycle numbers, as indicated). As shown,  -actin tran-
script was determined in parallel and used as a control. (B) Real-time
PCR was employed to confirm hypoxia inducibility of CD39 in cul-
tured endothelial cells (HMEC-1). Data were calculated relative to inter-
nal housekeeping gene ( -actin) and are expressed as fold increase over
normoxia   SD at each indicated time. Results are derived from three
experiments in each condition. (C) Human saphenous vein was obtained
from patients undergoing aorto-coronary bypass surgery and exposed ex
vivo to ambient normoxia (pO2 147 torr, 24 h) or hypoxia (pO2 20 torr
for 2, 8, or 24 h). After total RNA isolation, real-time PCR was per-
formed to investigate CD39 inducibility by hypoxia. Data were calculated
relative to internal control ( -actin) and are expressed as fold increase
over normoxia   SD at each indicated time. Results are derived from
three experiments in each condition. (D) Increase in surface CD39 sur-
face protein with hypoxic exposure. Confluent HMEC-1 monolayers
were exposed to indicated periods of hypoxia, monolayers were washed,
surface proteins were biotinylated, and cells were lysed. CD39 was im-
munoprecipitated with mAb directed against human CD39. Immuno-
precipitates were resolved by SDS-PAGE, and resultant Western blots
were probed with avidin-peroxidase. A representative experiment of
three is shown. (E) Validation etheno-ATP (E-ATP) and etheno-AMP
(E-AMP) resolution by HPLC. Shown is a representative tracing indicat-
ing resolution of definitive peaks at UV 260 nm. (F) Functional increase
in CD39 surface activity by hypoxia. Endothelial monolayers were ex-
posed to 48 h hypoxia or normoxia, washed, and surface CD39 activity
was determined by HPLC analysis of E-ATP conversion to E-AMP in
the presence of the CD73-inhibitor   -methylene-ADP (10  M, to
prevent further metabolism of E-AMP to E-adenosine). Data are derived
from five to seven monolayers in each condition, and results are ex-
pressed as E-AMP: E-ATP ratio   SD.T
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eral features of this response. As shown in Fig. 3 A this as-
sessment revealed prominent induction of CD39 mRNA
expression after 18 and 24 h of exposure to hypoxia (13  
2-fold increase of integrated band density in cells exposed
to hypoxia compared with those exposed to normoxia,
P   0.01), suggesting that CD39 is induced by hypoxia.
Moreover, comparison of HMEC-1 mRNA levels by real-
time PCR revealed that CD39 (Fig. 3 A) is prominently
induced by hypoxia. Similar results of CD39 inducibility
were found when human saphenous vein tissues were sub-
jected to hypoxia, indicating that such findings are not lim-
ited to cultured endothelium. Real time PCR analysis of
RNA preparations of saphenous vein revealed induction of
CD39 as early as 2 h of ex vivo exposure to hypoxia (Fig. 3
C, P   0.025 by ANOVA).
We extended these findings to determine if CD39 is
functionally relevant. Initially, we determined whether
CD39 protein was induced by hypoxia. As shown in Fig. 3
D, immunoprecipitation of CD39 from total surface bio-
tinylated protein revealed time-dependent induction of CD39
(range 12–48 h), with maximal protein levels observed at 48 h
(Fig. 3 D; no additional increase at 72 h; data not shown).
We then assessed whether hypoxia induced CD39 was func-
tional. To do this, we adopted an HPLC method to com-
pare the relative amounts of E-ATP metabolism to E-AMP
(in the presence of the CD73 inhibitor  , -methylene-ADP
[10  M] to inhibit further metabolism of E-AMP to
E-adenosine, see method validation in Fig. 3 E). As shown
in Fig. 3 F, exposure of HMEC-1 to hypoxia (48 h) induced
an increase in functional CD39 (ANOVA, P   0.01 relative
to normoxia), and represented a 22   5-fold increase in the
rate of E-ATP metabolism with preexposure to hypoxia.
Together, these data suggest a transcriptional induction of
CD39 by hypoxia, which manifests as readily measurable in-
creases in surface enzyme activity.
CD39 Hypoxia Induction Is Necessary for ATP Elicited In-
creases of Barrier Function in Posthypoxic Endothelial Cells.
After having shown that functional CD39 is induced by hy-
poxia, we examined if CD39 induction by hypoxia is neces-
rase which metabolizes ATP/ADP to 5 -AMP (26, 27).
Our previous work indicated that the ecto-nucleotidases
CD39 and CD73 (metabolizes extracellular AMP to aden-
osine) are readily induced in epithelia by hypoxia (18), thus
providing the possibility that extracellular metabolism of
ATP to adenosine is enhanced in the posthypoxic endothe-
lium. We therefore pursued the hypothesis that relative
levels of CD39 and CD73 are coordinately induced by hy-
poxia. First, we examined the relative impact of hypoxia
on HMEC-1 CD39. Semiquantitative RT-PCR analysis
(comparison of CD39 and control  -actin with increasing
PCR cycle numbers) was employed to determine the gen-
Figure 4. Role of CD39 in ATP-elicited changes of posthypoxic en-
dothelial permeability. (A) HMEC-1 were loaded with CD39-specific
siRNA, control ribonucleotide or mock treated (control) and exposed to
hypoxia or normoxia (48 h). Monolayers were washed, surface protein
was biotinylated, and cells were lysed. CD39 was immunoprecipitated
and resolved by SDS-PAGE, and resultant Western blots were probed
with avidin-peroxidase. As a control for specificity, CD73 protein induc-
tion by hypoxia was assessed in parallel. (B) Influence of CD39 suppres-
sion by siRNA on functional surface protein. HMEC-1 were loaded with
CD39-specific siRNA, control-ribonucleotide, or mock treated and
CD39 activity was determined by HPLC analysis of E-ATP conversion to
E-AMP (in the presence of the CD73-inhibitor   -methylene-ADP).
Data are derived from five to seven monolayers in each condition, and re-
sults are expressed as E-AMP: E-ATP ratio   SD. (C) Influence of CD39
suppression by siRNA on endothelial barrier. HMEC-1 were loaded with
CD39-specific siRNA, control ribonucleotide or mock treated (control),
exposed to hypoxia or normoxia (48 h), and permeability to 70 kD FITC
in the presence or absence of ATP (100  M) was assessed (*, P   0.01
compared with no ATP). Data are derived from six monolayers in each
condition, and data are expressed as mean   SD of percent control flux.T
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sary for the observed increase of barrier function in posthy-
poxic endothelial cells upon ATP exposure. As no specific
CD39 inhibitors have come available (28), we used RNA
interference to suppress CD39 induction by hypoxia and
studied the functional influence on permeability. Thus, we
loaded HMEC-1 with specific CD39-siRNA, and exposed
the cells to hypoxia. Immunoprecipitation of biotinylated
surface CD39-protein showed an induction of CD39 in un-
treated controls and in HMEC-1 loaded with control oligo-
nucleotide (Fig. 4 A). In contrast, normoxic and posthy-
poxic CD39 levels were decreased after loading with
specific CD39-siRNA. Moreover, CD73 induction by hy-
poxia was not affected by CD39 siRNA loading, and as
such, provided a specificity control for these experiments.
As additional insight, we determined whether siRNA
directed against CD39 was functional. First, we measured
enzymatic conversion of E-ATP to E-AMP in siRNA-
mediated CD39 deficient cells. In controls and in HMEC-1
loaded with control oligonucleotide, a 48 h exposure to
hypoxia was associated with a significant increase in CD39
functional activity (ANOVA, P   0.01; Fig. 4 B). In con-
trast, loading with specific CD39-siRNA obviated a func-
tional induction of CD39 enzyme activity, indicating that
such RNA suppression was effective at the functional
protein level. To determine the relative role of CD39 in
ATP-mediated changes in endothelial barrier function, we
investigated the influence of ATP on barrier function in
normoxic and posthypoxic endothelial cells following inhi-
bition of CD39 with specific siRNA. In controls and in
HMEC-1 loaded with a control oligonucleotide, ATP elic-
ited an approximate 60% decrease in permeability in post-
hypoxic endothelial cells, but not in normoxic cells (Fig. 4
C). In contrast, no significant ATP-induced change in bar-
rier was observed in either normoxic or posthypoxic endo-
thelial cells after suppression of CD39 with siRNA (P  
0.01). These results indicate that selective targeting of
CD39 by siRNA effectively neutralizes the influence of
ATP on changes in endothelial barrier.
Inhibition of CD73 Blocks ATP-mediated Changes in Post-
hypoxic Endothelial Permeability. We next addressed the
role of CD73 in ATP-mediated changes in permeability.
Our previous studies indicated that CD73 is important for
the maintenance of barrier function during interactions
with PMN or soluble PMN mediators (e.g., AMP; refer-
ence 23). Similarly, it was previously shown that AMP en-
hances epithelial barrier recovery via activation of surface
AdoRA2B receptors (11). As confirmation of our previous
findings in epithelia (18), we observed a time-dependent
induction of CD73 by hypoxia in endothelia (see Fig. 5 A).
To determine the functional role of CD73 in this response,
we addressed whether the specific CD73 inhibitor  , -
methylene ADP might block ATP-induced changes in the
posthypoxic endothelium. As shown in Fig. 5 B, the addi-
tion of increasing concentrations of  , -methylene ADP in
combination with ATP (100  M) resulted in a concentra-
tion-dependent inhibition of ATP-mediated changes in
permeability selectively in posthypoxic endothelia (P  
0.01). These findings suggest that the increment of CD73
induced by hypoxia is relevant to endothelial functional re-
sponses (permeability).
Hypoxia Induces AdoRA2B: Role in Coordinated Vascular
Permeability Regulation. Having demonstrated a func-
tional role for hypoxia-regulated CD39 and CD73 in en-
Figure 5. Induction of CD73 by hypoxia is necessary for ATP-elicited
increases in posthypoxic endothelial barrier function. (A) Induction of
endothelial CD73 by hypoxia. Real-time PCR was employed to confirm
hypoxia inducibility of CD73 in cultured endothelial cells (HMEC-1).
Data were calculated relative to internal control genes ( -actin) and are
expressed as fold increase over normoxia   SD at each indicated time.
Results are derived from three experiments in each condition. (B) Influ-
ence of CD73-inhibitor   -methylene-ADP on ATP-elicited changes of
endothelial permeability. Indicated concentrations of   -methylene-
ADP were added to HMEC-1 monolayers that were cultured under nor-
moxic or hypoxic conditions (48 h) and stimulated with 100  M ATP. In
normoxic HMEC-1, neither the addition of ATP, nor   -methylene-
ADP were associated with changes in paracellular flux. In contrast,
ATP-elicited changes in endothelial flux in posthypoxic HMEC-1 were
obviated in a concentration-dependent fashion (P   0.01 by ANOVA).
Data are derived from six monolayers in each condition. Data are ex-
pressed as mean   SD of percent control flux with HBSS only.T
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dothelial permeability, we next addressed how endpoint
signaling (i.e., adenosine receptor activation) is amplified
in posthypoxic endothelia. First, we profiled the relative
expression of adenosine receptors in normoxic and hy-
poxic (12 h exposure to pO2 20 torr) endothelial cells by
microarray analysis. For these experiments, nonimmortal-
ized HMVECs were used. Interestingly, these experi-
ments demonstrated that the AdoRA2B was selectively in-
duced by hypoxia (see Fig. 6 A, P   0.05 by ANOVA),
and that other isoforms were either not changed
(AdoRA3) or significantly down-regulated (AdoRA1 and
AdoRA2A). As shown in Fig. 6 B, these microarray results
were verified in HMEC-1 by real-time PCR in RNA de-
rived from endothelial cells exposed to a time course of
hypoxia, and consistently revealed that the AdoRA3 iso-
form remained unchanged, both AdoRA1 and AdoRA2A
levels were decreased at later time points of hypoxia (18
and 24 h, P   0.025), and that the AdoRA2B was in-
creased by as much as 4   05-fold (P   0.01 compared
with normoxia). Identical results were obtained with
HMVEC as an endothelial source (unpublished data). Ex-
tensions of these findings revealed that surface protein lev-
els of AdoRA2B were similarly increased by exposure of
HMEC-1 to hypoxia (Fig. 6 C).
Figure 6. Adenosine A2B receptor (AdoRA2B) in-
duction by hypoxia enhances barrier response. (A) Mi-
croarray analysis of individual adenosine receptors in
response to hypoxia (AdoRA1, AdoRA2A, AdoRA2B,
and AdoRA3). Confluent HMEC-1 were exposed to
normoxia or hypoxia (12 h exposure to pO2 20 torr)
and the relative expression of individual adenosine re-
ceptors was quantified from total RNA by microarray
analysis. Data are expressed as fold change   SD relative
to normoxia. (B) Real-time PCR analysis was employed
to confirm hypoxia-regulated expression of individual
adenosine receptors (AdoRA1, AdoRA2A, AdoRA2B,
and AdoRA3) in HMEC-1. Data were calculated rela-
tive to internal control ( -actin) and are expressed as
fold increase   SD over normoxia at indicated time
points. Results are derived from three experiments in
each condition (*, P   0.01 compared with normoxia).
(C) Increased AdoRA2B surface protein with hypoxia.
Confluent HMEC-1 monolayers were exposed to in-
dicated periods of hypoxia, monolayers were washed,
surface proteins were biotinylated, and cells were lysed.
AdoRA2B was immunoprecipitated with mAb to human
AdoRA2B and resolved by SDS-PAGE, and resultant
Western blots were probed with avidin-peroxidase. A
representative experiment of three is shown. (D) Hy-
poxia induction of AdoRA2B enhances barrier response
of HMEC-1 to adenosine. Indicated concentrations of
adenosine were added to HMEC-1 monolayers preex-
posed to normoxia or hypoxia (48 h). Addition of the
specific AdoRA2B-antagonist MRS 1754 (100 nM) sig-
nificantly shifted the adenosine dose response in post-
hypoxic endothelium (P   0.01 by ANOVA). Data
are derived from 6 monolayers in each condition. Data
are expressed as mean   SD of percent control flux.T
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To determine whether such hypoxia-induced AdoRA2B
expression was functional, endothelial permeability assays
were employed using the selective AdoRA2B antagonist
MRS1754 (29). As can be seen in Fig. 6 D, MRS 1754 (100
nM) significantly shifted the adenosine dose–response curve
to the right, but had little influence on adenosine responses
in normoxic endothelia. Such results suggest a relative im-
portance for the expression level of AdoRA2B and that
AdoRA2B responses are amplified in posthypoxic endothelia.
Increased Vascular Permeability in cd39-null Animals: Influ-
ence of Hypoxia. As proof of principle for these concepts
in vivo, we compared the influence of hypoxia on vascular
permeability in wild-type and cd39-null mice using a previ-
ously described model (22). After intravenous injection of
Evans-blue, we exposed animals to either normoxia or
normobaric hypoxia (8% O2 and 92% N2) for 4 h and mea-
sured Evans-blue tissue concentrations as a marker of endo-
thelial permeability to albumin. Interestingly, assessment of
Figure 7. Role of hypoxia-
induced CD39 in vivo: cd39-
deficient mice and age, weight,
and gender matched controls
were administered intravenous
Evans blue solution (0.2 ml of
0.5% in PBS) and exposed to
normobaric hypoxia (8% O2,
92% N2) or room air for 4 h.
Animals were killed and the co-
lon, muscle, kidney, brain, liver,
and lungs were harvested. Organ
Evans blue concentrations were
quantified following formamide
extraction (55 C for 2 h) by
measuring absorbances at 610
nm with subtraction of reference
absorbance at 450 nm. cd39-defi-
cient mice showed higher tissue
Evans-blue concentrations in all
organs (except muscle) in nor-
moxic and hypoxic conditions as
compared with wild-type ani-
mals (*, P    0.05). Hypoxic
wild-type and cd39-deficient
mice showed higher tissue Evans
blue concentrations than nor-
moxic mice, with the exception
of hypoxic colon of the cd39-
deficient mice (#, P    0.05).
Data are expressed as mean  
SD Evans blue OD/mg wet tis-
sue, and are pooled from four to
six animals per condition. Images
of abdominal dissections (B) and
isolated colons (C) from wild-
type and cd39-deficient mice
subjected to normoxia and hy-
poxia. Note increased Evans blue
retention with hypoxia and
marked differences between
wild-type and cd39-deficient an-
imals under both conditions.T
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permeability in nonhypoxic cd39-null animals revealed
subtle, but significant increases in all tissues examined, with
the exception of skeletal muscle (Fig. 7 A). Consistent with
previous studies (3, 30), this model of hypoxia significantly
increased permeability in all wild-type control organs ex-
amined (Fig. 7 A, P   0.025 for all). Most importantly, and
as shown in Fig. 7 A, this analysis revealed amplified in-
creases in vascular permeability of all organs of cd39-null
animals. Gross morphologic changes in overall vascular
permeability (Evans blue retention) between hypoxia and
normoxia as well as wild-type and cd39-null were evident
in open abdominal images taken at necropsy (Fig. 7 B) and
were demonstrable in dissected organs such as the colon
(Fig. 7 C). These findings in vivo support our hypothesis
that CD39 is a critical determinant for permeability
changes associated with adenine nucleotide metabolism in
the posthypoxic vasculature.
Discussion
The vascular endothelium is the predominant interface
between the hypoxic insult and surrounding tissues. Simul-
taneously, the endothelium provides the primary determi-
nant of vascular permeability (31). As such, PMN influx
across the protective endothelium, such as occurs during
ischemia-reperfusion, creates the potential for endothelial
barrier dysfunction, loss of fluid and edema formation (7,
32). In this study we compared the direct influence of acti-
vated PMN on paracellular permeability in normoxic and
posthypoxic endothelial cells. The results revealed the ex-
istence of PMN-derived mediator(s), which selectively
promote posthypoxic endothelia. This mediator was iden-
tified as ATP based on its chemical characteristics and
chromatographic behavior. Further studies demonstrated
that hypoxia promotes the induction of CD39, an endo-
thelial surface apyrase responsible for the initiation of ATP
phosphohydrolysis to adenosine (33). We show here that
increased activity of endothelial CD39, as seen after hy-
poxic exposure, is necessary for the barrier protective in-
fluence of ATP. Similarly, these studies revealed that ad-
ditional metabolic and signaling molecules (CD73 and
AdoRA2B, respectively) are coordinately induced by hy-
poxia (Fig. 8). In vivo relevance for this response revealed
that cd39-null mice are more susceptible to the develop-
ment of endothelial barrier dysfunction during hypoxia ex-
posure. Taken together, these studies identify a pathway
which results in both elevated tissue levels of adenosine
and in amplified endothelial responses to adenosine gener-
ated at sites of hypoxia.
It is well documented that adenosine tissue and plasma
levels are increased during hypoxia, however, mechanisms
of this response are less clear (34, 35). For example, in hu-
man volunteers exposed to ambient hypoxia (SpO2   80%
over 20 min), plasma adenosine concentrations increased
from 21 to 51 nM in the presence of dipyridamole, an in-
hibitor of adenosine reuptake (36). Similarly, when mea-
suring adenine nucleotide concentrations in the neurally
and vascularly isolated, perfused skeletal muscles of anesthe-
tized dogs, normobaric hypoxia is associated with increases
of adenosine in the venous blood, but not of AMP, ADP,
or ATP (37). In conjunction with these studies, we de-
scribe here a metabolic pathway, which results in increased
tissue adenosine concentrations. While it is well docu-
mented that adenosine levels are increased in hypoxic tis-
sue, the source of adenosine remains unclear. We show
here, for the first time, that PMN actively release ATP to
the extracellular milieu. At present, we do not know the
origin of ATP release. Several mechanisms for ATP release
have been proposed, including direct transport through
ATP-binding cassette (ABC) proteins, transport through
connexin hemichannels, as well as vesicular release (38). As
part of the present experiments, some studies were done in
an attempt to identify the compartmentalization of ATP
(unpublished data). For example, we compared the kinetics
Figure 8. Proposed model of coordinated
nucleotide metabolism and nucleoside sig-
naling in posthypoxic endothelial cells: in
areas of ongoing inflammation, diminished
oxygen supply coordinates the induction of
CD39, CD73, and AdoRA2B. At such sites,
activated PMN provide a readily available
extracellular source of ATP that through
two enzymatic steps results in the liberation
of extracellular adenosine. Adenosine gener-
ated in this fashion is available for activation of
surface endothelial adenosine receptors, par-
ticularly the AdoRA2B. Postreceptor in-
creases in intracellular cyclic AMP results in
enhanced barrier function. As such, this
protective mechanism may provide an in-
nate mechanism to preserve vascular integ-
rity and prevent fulminant intravascular
fluid loss.T
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of ATP release with activated release of PMN granules
(myeloperoxidase, MPO). These studies indicated that
while ATP levels were maximal within 1 min, activated
degranulation contents such as MPO were maximal at time
points  5 min, suggesting that ATP is not granule bound.
Moreover, in experiments using isolated granules from un-
activated PMN,  95% of MPO activity was associated
with granules,  5% of ATP was measurable within this
granule pool, suggesting that ATP is unlikely to be gran-
ule-bound in PMN. At present, the mechanism by which
leukocytes release ATP remains unclear.
As part of these studies, we found that targeted disruption
of CD39 in an animal model of ambient hypoxia was asso-
ciated with barrier dysfunction at baseline and after hypoxic
exposure. Such increases in permeability in the cd39-null
mice may be related to decreased concentrations of adeno-
sine and activation of endothelial adenosine receptors. In
addition, activation of neutrophil A2 adenosine receptors
has been shown to play a critical part for the limitation and
termination of PMN-mediated systemic inflammatory re-
sponses (39, 40). Thus, it is reasonable to propose that the
presence of CD39/CD73 is important in modulating in-
flammatory responses during hypoxia. Coordinated induc-
tion of both CD39 and CD73 by hypoxia may provide in-
creased tissue adenosine concentrations, thus leading to
increased stimulation of PMN adenosine A2-receptors and
decreased leukocyte adherence and transmigration, as has
been demonstrated by others (41, 42). Moreover, recent
studies have indicated that adenosine A2A-receptors may
contribute to attenuated vascular leak associated with leu-
kocyte accumulation (43). As such, direct influences of
adenosine via hypoxia-amplified CD39 and CD73 may
provide antiinflammatory synergism with the observed pro-
tection of endothelial barrier during hypoxia.
As outlined above, leukocyte transmigration associated
with hypoxic/ischemic tissues creates the potential for dis-
turbance of the endothelial barrier. We have previously
shown that adenosine activation of AdoRA2B leads to a
barrier resealing response after PMN transmigration (11).
Activation of the AdoRA2B is associated with increases in
intracellular cAMP concentration following activation of
the adenylate cyclase (44). By inhibition of cAMP forma-
tion, the resealing of the endothelial barrier during PMN
transmigration can be obviated (11). Such increases in
cAMP after activation of the AdoRA2B lead to an activa-
tion of protein kinase A (PKA; reference 12). Further stud-
ies revealed a central role of PKA-induced phosphorylation
of vasodilator-stimulated phosphoprotein (VASP), a pro-
tein responsible for controlling the geometry of actin-fila-
ments (45). Adenosine-receptor mediated phosphorylation
of VASP is responsible for changes in the geometry and
distribution of junctional proteins, thereby affecting the
characteristics of the junctional complex and promoting in-
creases in barrier function (12).
We show here that the barrier-protective response to ex-
tracellular ATP is most prevalent in posthypoxic endothelial
cells. After suppression of CD39 induction with specific
siRNA, this barrier-protective influence to ATP is obvi-
ated, providing insight that this molecule may efficiently co-
ordinate permeability responses to PMN during inflamma-
tion and hypoxia. In parallel, we showed that the ecto-
nucleotidase CD73 is similarly induced by hypoxia. These
findings in endothelia coincide with recent work in epithe-
lia identifying a predominant role for hypoxia-inducible fac-
tor-1 (HIF-1) in CD73 induction by hypoxia (18) and re-
cently in enothelial cells (46). Currently, the mechanism for
the hypoxia-inducibility of AdoRA2B and CD39 remains
unclear. Relatively little is known about the transcriptional
regulation of CD39 and AdoRA2B, and while HIF-1 is cur-
rently an area of intense investigation in a variety of disor-
ders (47), including inflammation (5, 17, 18), it remains to
be seen whether the coordinated transcription of CD39,
CD73, and AdoRA2B have common regulatory elements.
Some precedent exists for coordinated, metabolic re-
sponses to hypoxia. For example, in the regulation of oxy-
gen hemostasis, HIF-1 has been shown to regulate multiple
metabolic and compartmental steps in several metabolic
pathways (47). As such, at least 13 different genes encoding
glucose transporters and glycolytic enzymes are coordi-
nately decreased in HIF-1 deficiency (47). Similarly in the
present study, transcriptional and metabolic control-points
of extracellular nucleotide metabolism and nucleoside sig-
naling are controlled in a coordinated fashion. Interest-
ingly, recent evidence indicates that the AdoRA2A and
CD73 are coordinately regulated by mitogenic stimuli in
human B cells, and that such a pathway drives increased
signal transduction (48). The present results of a coordi-
nated response to decreased oxygen availability of CD39,
CD73, and the AdoRA2B suggest a similar evolutionary
adaption to hypoxia.
In summary, these results define a previously unappreci-
ated metabolic pathway prevalent at the vascular interface
during inflammation/hypoxia. We show here that PMN-
derived ATP selectively promotes barrier function of post-
hypoxic endothelia. The observed differences were attribut-
able to a coordinated transcriptional response initiated by
hypoxia, and resulting in amplified metabolism of extracel-
lular ATP to adenosine as well as enhanced signaling
through the AdoRA2B. We propose that this feed-forward
mechanism may contribute an endogenous, protective path-
way for highly vascular tissues during adaptation to hypoxia.
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